Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409058 | 0.84 | L3MBTL1 (0.66) | L3MBTL1KDM4EMAOBAOC3MRGPRX4 | |
| SCHEMBL3197958 | 0.84 | SOD1 (0.51) | L3MBTL1LMNANR4A2POLB | |
| SCHEMBL12072717 | 0.83 | L3MBTL1 (0.60) | L3MBTL1KDM4EMAOBAOC3MRGPRX4 | |
| SCHEMBL5953372 | 0.81 | L3MBTL1 (0.71) | L3MBTL1KDM4EMAOBAOC3MRGPRX4 | |
| SCHEMBL30628214 | 0.81 | MRGPRX4 (0.45) | KDM4EMAOBMRGPRX4LMNAPKM | |
| SCHEMBL17420544 | 0.81 | MRGPRX4 (0.45) | KDM4EMAOBMRGPRX4LMNAPKM | |
| SCHEMBL1607526 | 0.80 | MAOB (0.48) | KDM4EMAOBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL16024758 | 0.80 | L3MBTL1 (0.50) | L3MBTL1KDM4EMAOBAOC3MRGPRX4 | |
| SCHEMBL30167649 | 0.79 | L3MBTL1 (0.55) | L3MBTL1KDM4EMAOBAOC3MRGPRX4 | |
| SCHEMBL167016 | 0.79 | L3MBTL1 (0.58) | L3MBTL1KDM4EMAOBLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102020647-B | Preparation method of 1-(2,2-difluoroethoxy)-6-trifluoromethyl-N-([1,2,4]triazolezol[1,5-C] pyrimidine-2-)benzsulfamide | SUN ZHIHUA | 2013-09-11 | — | — | CN | claimed |
| CN-102020647-A | Preparation method of 1-(2,2-difluoroethoxy)-6-trifluoromethyl-N-([1,2,4]triazolezol[1,5-C] pyrimidine-2-)benzsulfamide | ZHIHUA SUN | 2011-04-20 | — | — | CN | claimed |
| EP-4112599-A1 | KEY INTERMEDIATE FOR SYNTHESIZING PROSTAGLANDIN COMPOUNDS AND PREPARATION METHOD THEREFOR | SHENZHEN CATALYS TECHNOLOGY CO., LTD. (CN) | 2023-01-04 | — | — | EP | disclosed |
| CN-110590623-B | Method for preparing 6-substituted-2-trifluoromethyl phenyl sulfide in continuous flow microchannel reactor | 江苏好收成韦恩农化股份有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-110590623-A | Method for preparing 6-substituted-2-trifluoromethyl phenyl sulfide in continuous flow microchannel reactor | 江苏好收成韦恩农化股份有限公司 | 2019-12-20 | — | — | CN | disclosed |
| EP-2697213-B1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | HIVIH (FR) | 2018-12-12 | — | — | EP | disclosed |
| US-9604900-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2017-03-28 | — | — | US | disclosed |
| US-9604900-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2017-03-28 | — | — | US | disclosed |
| US-9604900-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2017-03-28 | — | — | US | disclosed |
| EP-2697213-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-02-19 | — | — | EP | disclosed |
| US-20140031338-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-01-30 | — | — | US | disclosed |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| CN-1694873-A | Vanilloid receptor ligands and their use in treatments | AMGEN INC (US) | 2005-11-09 | — | — | CN | disclosed |
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1290001-B1 | PROCESS FOR THE SELECTIVE DEPROTONATION AND FUNCTIONALIZATION OF 3-SUBSTITUTED BENZOTRIFLUORIDES | DOW AGROSCIENCES LLC (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| US-6462240-B2 | FROMING 2-LITHIOBENZOTRIFLORIDE FROM BENZOTRIFLUORIDE AND ALKYLLITHIUM | DOW AGROSCIENCES LLC | 2002-10-08 | — | — | US | disclosed |
| US-20020010375-A1 | Process for the selective deprotonation and functionalization of 3-substituted benzotrifluorides | CORTEVA AGRISCIENCE LLC | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031338-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | POLRMT, MAVS, EIF2AK2 | L3MBTL1 1958/4885KDM4E 1408/4885MAOB 2144/4885 |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | L3MBTL1 4532/4885KDM4E 4218/4885MAOB 1213/4885 |
| US-20020010375-A1 | Process for the selective deprotonation and functionalization of 3-substituted benzotrifluorides | BPTF, FGFR2, FGFR4 | L3MBTL1 1258/4885KDM4E 1239/4885MAOB 920/4885 |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | L3MBTL1 4532/4885KDM4E 4218/4885MAOB 1213/4885 |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | L3MBTL1 4422/4885KDM4E 4111/4885MAOB 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.